LOVE — Cannara Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- CA$75.62m
- CA$121.63m
- CA$57.56m
- 43
- 94
- 35
- 58
Annual cashflow statement for Cannara Biotech, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2019 August 31st | 2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13 | -13.1 | -1.53 | 2.31 | 6.95 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 4.74 | 1.48 | 0.229 | -0.822 | -0.337 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.266 | -0.29 | -3.82 | -11.5 | -6.11 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -7.4 | -9.32 | -2.09 | -6.08 | 5.44 |
| Capital Expenditures | -23 | -9.18 | -30.6 | -15.1 | -9.31 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1.37 | 0.631 | -0.223 | -0.25 | -0.166 |
| Sale of Fixed Assets | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -21.6 | -8.55 | -30.8 | -15.3 | -9.48 |
| Financing Cash Flow Items | 3.27 | -1.13 | -1.49 | -1.61 | -4.15 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 42.7 | -0.915 | 33.3 | 25.5 | -3.72 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 13.6 | -18.7 | 0.388 | 3.96 | -7.84 |